ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,877 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselTOLREMO therapeutics AG
TOLREMO therapeutics AG Logo
Verified· 4 sources

TOLREMO therapeutics AG

Summary

About the company

The core activity of TOLREMO therapeutics AG is the development of therapeutic solutions to combat cancer, particularly to overcome cancer resistance to targeted therapies. The company focuses on the development of active ingredients that are intended to inhibit the early transcriptional reprogramming of cancer cells, the first line of defense against targeted therapies, in order to improve the efficacy of cancer treatments.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered3
Development of cancer therapies against non-genetic drug resistance
Development of small molecules and therapeutic approaches to block transcriptional reprogramming, preventing early and acquired cancer drug resistance.
Development of TT125-802
Development of the orally available, selective CBP/p300 bromodomain inhibitor TT125-802 as monotherapy and in combination with targeted therapies in solid tumors and haematological malignancies.
Clinical development of TT125-802
Phase I dose-escalation study of TT125-802 as monotherapy in patients with solid tumors, along with further clinical development with targeted therapies.
Reviews

Aggregated rating

Aggregated rating
5
of 5

Aggregated from 2 reviews across all connected sources

Sources
GGoogle52
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Press

Media

July 8, 2022Media
Tolremo’s founder Stefanie Flückiger-Mangual is the Innovator of the Year
startupticker.ch
June 10, 2020Media
Additional capital for TOLREMO therapeutics
startupticker.ch
September 24, 2018Media
TOLREMO raises CHF9 million series A financing round
startupticker.ch
September 19, 2017Media
Biotech start-up TOLREMO closes CHF2,4 million financing round
startupticker.ch

Knowledge

No knowledge articles yet

Once TOLREMO therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

TOLREMO therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank TOLREMO therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of TOLREMO therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hochbergerstrasse 60C
4057 Basel

At a glance

Legal form
Corporation
UID
CHE-350.476.582
Founded
2017 · 9 years
Last commercial register change
November 25, 2025
Employees
11 to 20

Similar companies

MB
MabTree Biologics AG
Basel
IA
Intex-Biotech AG
Basel
LS
Latscha Schöllhorn Partner AG
Basel
AS
Accense S.A.
Basel